PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 128 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $835,885 | -51.8% | 50,113 | -20.2% | 0.00% | -50.0% |
| Q2 2023 | $1,735,475 | +98.6% | 62,834 | +65.3% | 0.00% | +100.0% |
| Q1 2023 | $874,023 | +156.5% | 38,001 | +21.7% | 0.00% | – |
| Q4 2022 | $340,796 | +26.2% | 31,237 | -2.5% | 0.00% | – |
| Q3 2022 | $270,000 | +7.6% | 32,032 | +0.7% | 0.00% | – |
| Q2 2022 | $251,000 | -67.8% | 31,815 | -3.3% | 0.00% | -100.0% |
| Q1 2022 | $779,000 | -19.6% | 32,898 | +16.1% | 0.00% | 0.0% |
| Q4 2021 | $969,000 | +97.4% | 28,348 | +2.4% | 0.00% | – |
| Q3 2021 | $491,000 | -60.1% | 27,695 | +0.9% | 0.00% | -100.0% |
| Q2 2021 | $1,231,000 | +124.2% | 27,455 | +29.3% | 0.00% | – |
| Q1 2021 | $549,000 | -46.4% | 21,240 | -58.2% | 0.00% | -100.0% |
| Q4 2020 | $1,025,000 | +90.9% | 50,823 | +85.0% | 0.00% | – |
| Q3 2020 | $537,000 | +50.0% | 27,476 | +62.3% | 0.00% | – |
| Q3 2016 | $358,000 | – | 16,924 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pharmstandard International S.A. | 750,632 | $7,724,000 | 26.59% |
| BVF INC/IL | 2,617,967 | $26,939,000 | 2.37% |
| GREAT POINT PARTNERS LLC | 982,449 | $10,109,000 | 1.58% |
| Alambic Investment Management, L.P. | 65,128 | $670,000 | 0.53% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,243,202 | $23,083,000 | 0.14% |
| ALGERT GLOBAL LLC | 44,477 | $458,000 | 0.10% |
| Monashee Investment Management LLC | 42,945 | $442,000 | 0.09% |
| Tekla Capital Management LLC | 219,042 | $2,254,000 | 0.08% |
| Spark Investment Management LLC | 138,800 | $1,428,000 | 0.08% |
| OXFORD ASSET MANAGEMENT LLP | 187,653 | $1,904,000 | 0.04% |